• 1
    Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295306.
  • 2
    Erkan D, Lockshin MD. Non-criteria manifestations of antiphospholipid syndrome. Lupus 2010; 19: 4247.
  • 3
    Youinou P, Renaudineau Y. The antiphospholipid syndrome as a model for B-cell-induced autoimmune diseases. Thromb Res 2004; 114: 3639.
  • 4
    Khattri S, Zandman-Goddard G, Peeva E. B-cell directed therapies in antiphospholipid antibody syndrome—new directions based on murine and human data. Autoimmun Rev 2012; 11: 71722.
  • 5
    Kahn P, Ramanujam M, Bethunaickan R, Huang W, Tao H, Madaio MP, et al. Prevention of murine antiphospholipid syndrome by BAFF blockade. Arthritis Rheum 2008; 58: 282434.
  • 6
    Akkerman A, Huang W, Wang X, Ramanujam M, Sciffer L, Madaio M, et al. CTLA4Ig prevents initiation but not evolution of antiphospholipid syndrome in NZW/BXSB mice. Autoimmunity 2004; 37: 44551.
  • 7
    Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-specific antigen. J Immunol 1980; 125: 167885.
  • 8
    Rituxan (rituximab) prescribing information. South San Francisco (CA): Biogen Idec and Genentech; 2011.
  • 9
    Van Vollenhoven RF. Rituximab—shadow, illusion, or light? Autoimmun Rev 2012; 11: 5637.
  • 10
    Rubenstein E, Arkfeld DG, Metyas S, Shinada S, Ehresmann S, Liebman HA. Rituximab treatment for resistant antiphospholipid syndrome. J Rheumatol 2006; 33: 3557.
  • 11
    Erdozain JG, Ruiz-Irastorza G, Egurbide MV, Aguirre C. Sustained response to rituximab of autoimmune hemolytic anemia associated with antiphospholipid syndrome. Haematologica 2004; 89: ECR34.
  • 12
    Tenedios F, Erkan D, Lockshin MD. Rituximab in the primary antiphospholipid antibody syndrome [abstract]. Arthritis Rheum 2005; 52: 4078.
  • 13
    Kumar D, Roubey RA. Use of rituximab in the antiphospholipid syndrome. Curr Rheumatol Rep 2010; 12: 404.
  • 14
    Espinosa G, Berman H, Cervera R. Management of refractory cases of catastrophic antiphospholipid syndrome. Autoimmun Rev 2011; 10: 6648.
  • 15
    Scoble T, Wijetilleka S, Khamashta MA. Management of refractory antiphospholipid syndrome. Autoimm Rev 2011; 10: 66973.
  • 16
    Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, et al. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009; 7: 173740.
  • 17
    ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42: 599608.
  • 18
    Kozora E, Ellison MC, West S. Reliability and validity of the proposed American College of Rheumatology neuropsychological battery for systemic lupus erythematosus. Arthritis Rheum 2004; 51: 8108.
  • 19
    Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
  • 20
    Ware JE Jr, Sherbourne CD. The MOS 36-item Short-Form health survey (SF-36) I Conceptual framework and item selection. Med Care 1992; 30: 47383.
  • 21
    Gladsjo JA, Schuman CC, Evans JD, Peavy GM, Miller SW, Heaton RK. Norms for letter and category fluency: demographic corrections for age, education and ethnicity. Assessment 1999; 6: 14778.
  • 22
    Chan OT, Hannum LG, Haberman AM, Madaio MP, Shlomchik MJ. A novel mouse with B cells but lacking serum antibody reveals an antibody independent role for B cells in murine lupus. J Exp Med 1999; 189: 163948.
  • 23
    Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007; 44: 382337.
  • 24
    Ames PR, Tommasino C, Fossati G, Scenna G, Brancaccio V, Ferrara F. Limited effect of rituximab on thrombocytopaenia and anticardiolipin antibodies in a patient with primary antiphospholipid syndrome. Ann Hematol 2007; 86: 2278.
  • 25
    Tommasino C, Fossati G, Saulino A, Margarita A, Ferrara F, Iannaccone L, et al. Short-term lack of efficacy of rituximab in a thrombocytopaenic patient with primary antiphospholipid syndrome [abstract]. Thromb Res 2004; 114: 652.
  • 26
    Trappe R, Loew A, Thuss-Patience P, Dorken B, Riess H. Successful treatment of thrombocytopenia in primary antiphospholipid antibody syndrome with the anti-CD20 antibody rituximab—monitoring of antiphospholipid and anti-GP antibodies: a case report. Ann Hematol 2006; 85: 1345.
  • 27
    Sciascia S, Naretto C, Rossi D, Bazzan M, Roccatello D. Treatment-induced downregulation of antiphospholipid antibodies: effect of rituximab alone on clinical and laboratory features of antiphospholipid syndrome. Lupus 2011; 20: 11068.
  • 28
    Cooper N, Stasi R, Cunningham-Rundles S, Feuerstein MA, Leonard JP, Amadori S, et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Hematol 2004; 125: 2329.
  • 29
    Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol 2005: 78; 27580.
  • 30
    Skyrme-Jones RA, Wardrop CA, Wiles CM, Fraser AG. Transesophageal echocardiographic demonstration of resolution of mitral vegetations after warfarin in a patient with the primary antiphospholipid syndrome. J Am Soc Echocardiogr 1995; 8: 2516.
  • 31
    Espinola Zavaleta N, Montes RM, Soto ME, Vanzzini NA, Amigo MC. Primary antiphospholipid syndrome: a 5 year transesophageal echocardiographic follow up study. J Rheumatol 2004; 31: 24027.
  • 32
    Gertner E, Lie JT. Systemic therapy with fibrinolytic agents and heparin for recalcitrant nonhealing cutaneous ulcer in the antiphospholipid syndrome. J Rheumatol 1995; 21: 215961.
  • 33
    Costa R, Fazal S, Kaplan RB, Spero J, Costa R. Successful plasma exchange combined with rituximab therapy in aggressive APS-related cutaneous necrosis. Clin Rheumatol 2010. E-pub ahead of print.
  • 34
    Tsagalis G, Psimenou E, Nakopoulou L, Laggouranis A. Effective treatment of antiphospholipid syndrome with plasmapheresis and rituximab. Hippokratia 2010; 14: 2156.
  • 35
    Shoenfeld Y, Nahum A, Korczyn AD, Dano M, Rabinowitz R, Beilin O, et al. Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer. Lupus 2003; 12: 43642.